ZYME - Zymeworks Inc. News

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34

Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises t

marketbeat.com

Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook

Zymeworks NASDAQ: ZYME said it has completed its acquisition of Theravance Biopharma, adding the COP

Citigroup Maintains Buy on Zymeworks, Raises Price Target to $39

Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the p

Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal

Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains re

Zymeworks Sees FY2026 Sales $278.000M-$292.000M vs $302.577M Est

Zymeworks (NASDAQ:ZYME) sees FY2026 sales of $278.000 million-$292.000 million vs $302.577 million a

Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And

Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare as

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravan

VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a bi

Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME

Bank of America Corp DE purchased a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) during t

Zymeworks Completes Acquisition of Theravance Biopharma

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a bio

Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Jupiter Topco LLC Buys New Position in Zymeworks Inc. $ZYME

Jupiter Topco LLC bought a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) in the undefined

JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $33

JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the

Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval

Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-genera

Bank of America Corp DE Raises Position in Zymeworks Inc. $ZYME

Bank of America Corp DE lifted its stake in Zymeworks Inc. (NASDAQ: ZYME) by 164.5% during the undef

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its mark

Citigroup Maintains Buy on Zymeworks, Raises Price Target to $38

Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the p

Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks

U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings

MongoDB To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT

Citizens Reiterates Market Outperform on Zymeworks, Maintains $32 Price Target

Citizens analyst Reni J. Benjamin reiterates Zymeworks (NASDAQ:ZYME) with a Market Outperform and

HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $55

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and rai

Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens

FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positiv

Jazz Pharmaceuticals' Two Ziihera-Containing Regimens Receives FDA Approval To Treat Adults With Unr

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (F

Deutsche Bank AG Buys Shares of 397,190 Zymeworks Inc. $ZYME

Deutsche Bank AG purchased a new stake in Zymeworks Inc. (NASDAQ: ZYME) in the second quarter, accor

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow amprelo

B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $44

B. Riley Securities analyst Mayank Mamtani reiterates Zymeworks (NASDAQ:ZYME) with a Buy and rais

Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $40

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and ra

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $32

Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises t

Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus E

Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million

HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $51

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and rai

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biot

Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $31

Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises t

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma

Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cas

Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $37

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and ra

Theravance Stock Down 3% After Zymeworks Announces Buyout

TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic

Zymeworks Inc. (ZYME) M&A Call Transcript

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition

Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:

Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expandin

Theravance Biopharma Discloses Termination Fee Of $32.5M After Acquisition Offer By Zymeworks

The Merger Agreement contains certain customary termination rights for the Company and Parent. Subje

reuters.com

Zymeworks strikes $929 million deal for Theravance Biopharma

Drugmaker Zymeworks ‌said on Monday ⁠it will buy Theravance Biopharma in ‌a $929 ⁠million de

Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M

Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarini

Reported Sunday, Zymeworks Presents Phase 1 Data For ZW191 ADC Showing 78.6% cORR In FRα-Positive An

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients rega

Zymeworks Announces Jazz Pharmaceuticals To Present Four Abstracts Featuring Data From Clinical Stud

Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare a

12 Health Care Stocks Moving In Monday's Pre-Market Session

BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Sessi

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-

Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr

Earnings Scheduled For March 2, 2026

Zymeworks And Royalty Pharma Enter Into $250M Funding From Royalty-backed Note With Repayments Due F

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with rep